Loading viewer...
investor_presentation
Format: PDF investor_presentation
J. Michael Bruff Senior Vice President, Investor Relations investors@varian.comApril 25, 2018Second Quarter Fiscal Year 2018
Senior Vice President, Investor Relations
investors@varian.comApril 25, 2018Second Quarter
This presentation is intended exclusively for investors.
It is not intended for use in Sales or Marketing.
2Forward -Looking Statements
Except forhistorical information, thispresentation contains forward -looking statements within themeaning ofthePrivate Securities Litigation Reform Actof1995 .Statements
concerning industry outlook, including growth drivers, future trends incancer incidence andtrends incancer treatment needs, demand, innovation andgrowth opportunities ;Varian
Medical System, Inc.’s(”Varian” orthe“company”) future orders, revenues, backlog orearnings growth ;future financial results ;statements concerning Varian’s planned acquisition
ofSirtex ,expected synergies, accretive expectations, estimated closing date oftheSirtex acquisition, andthecompany’s ability toclose andintegrate theSirtex acquisition and
achieve expected synergies ;market acceptance ofortransition tonew products ortechnology such asourEdge®radiosurgery system, TrueBeam®,HyperArcTM,360OncologyTM,
HALCYONTM,image -guided radiation therapy, stereotactic radiosurgery andproton therapy, andanystatements using theterms “could”, “believe”, “expect”, “outlook”, “anticipate”,
”vision”, “estimate”, “future”, “horizon”, “aiming”, “driving”, “target” orsimilar statements areforward -looking statements that involve risks and uncertainties that could cause the
company’s actual results todiffer materially from those anticipated .Such risks anduncertainties include global economic conditions andchanges totrends forcancer treatment
regionally ;theimpact ofchanges totheAffordable Health Care forAmerica Act(including excise taxes onmedical devices) andanyfurther healthcare reforms (including changes to
Medicare andMedicaid), and/or changes tothird-party reimbursement levels ;currency exchange rates andtaxrates ;theimpact oftheTaxCuts andJobs Act;demand forthe
company’s products ;thecompany’s ability todevelop, commercialize, and deploy new products ;thecompany’s ability tomeet Food andDrug Administration (FDA) andother
regulatory requirements forproduct clearances ortocomply with FDA andother regulatory regulations orprocedures, changes intheregulatory environment, including withrespect
toFDA requirements ;thecompany’s assessment ofthegoodwill associated with itsparticle therapy business, challenges associated with thesuccessful commercialization ofthe
company’s particle therapy business ;therisks associated with providing financing fortheconstruction and start-upoperations ofproton therapy centers ;theeffect ofadverse
publicity ;thecompany’s reliance onsole orlimited -source suppliers ;thecompany’s ability tomaintain orincrease margins ;theimpact ofcompetitive products andpricing ;the
potential loss ofkeydistributors orkeypersonnel ;challenges topublic tender awards andthelossofsuch awards orother orders ;andtheother risks listed from time totime inthe
Preview truncated — download the full document for the complete content.
conference
27 Pages
investor_presentation
LumiraDx
Iovance Biotherapeutics Investor Presentation — January 2019
investor_presentationinvestor_presentation
34 Pages
Iovance Biotherapeutics, Inc